First Turn Management, LLC
DEL MAR, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$753.0M2026 Q3
Positions38
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.43.9%
What Changed This Quarter?
Top Holdings
ELVN
Enliven Therapeutics
5.8%
GH
Guardant Health
5.2%
ABVX
Abivax S.A.
5.1%
ROIV
Roivant Sciences
4.8%
UTHR
United Therapeutics
4.3%
VRDN
Viridian Therapeutics
4.2%
AXSM
Axsome Therapeutics
4.0%
INSM
Insmed
3.7%
New / Increased
13 new · 5 increased
GHNEW
Guardant Health
5.2%
CRLNEW
Charles Riv Labs
3.4%
RGENNEW
Repligen
2.8%
TNGXNEW
Tango Therapeutics
2.5%
MANENEW
Veradermics
2.2%
NAMS
Newamsterdam Pharma
2.3%
+20.6%
KYMR
Kymera Therapeutics
1.7%
+10.5%
INBX
Inhibrx Biosciences
2.3%
+4.1%
Reduced / Exited
19 reduced · 6 sold out
RVMD
Revolution Medicines
2.5%
-77.8%
BBIO
Bridgebio Pharma
3.1%
-44.0%
PCVX
Vaxcyte
1.0%
-69.0%
UTHR
United Therapeutics
4.3%
-29.3%
ROIV
Roivant Sciences
4.8%
-26.0%
MIRMEXIT
Mirum Pharmaceuticals
2.7%
Apogee Therap…EXIT
Apogee Therapeutics
2.0%
SRRKEXIT
Scholar Rock
1.6%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.